Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Stapokibart (CM310) in Children with Atopic Dermatitis
NCT06162507Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Dec 2023; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06162507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162507.